News | January 21, 2009

Ultrasound Delivery of Clot-Busting Drugs May Lessen Risk of Bleeding in Thrombolysis

January 22, 2009 - Delivering clot-busting drugs with an ultrasound-enhanced delivery system could reduce the amount of drugs needed to break up dangerous blood clots in the legs and pelvis, according to discussions surrounding a live case demonstration at the 21st annual International Symposium on Endovascular Therapy (ISET).

In a live case preformed yesterday viewed by hundreds of endovacular specialists, Constantino Peña, M.D., an interventional radiologist at Baptist Cardiac and Vascular Institute in Miami, treated a 74-year-old male with a blocked leg artery. Dr. Peña delivered the drug Tenecteplase (TNK) to the clot via ultrasound-accelerated catheter-directed thrombolysis, and the clot was completely dissolved upon examination 12 hours later.

In a discussion of the live case, Dr. Peña indicated that the amount of TNK used to dissolve the clot was half what is typically used. Lowering the amount of drug needed to dissolve clots can significantly reduce the risk of major bleeding, according to Barry Katzen, M.D., founder and medical director of Baptist Cardiac and Vascular Institute.

The International Symposium on Endovascular Therapy (ISET) is attended by more than 1,200 physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live cases to promote the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET is presented by the Baptist Cardiac and Vascular Institute, Miami.

For more information: www.ISET.org


Related Content

News | Pharmaceuticals

Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...

Home November 19, 2025
Home
News | Pharmaceuticals

Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...

Home September 25, 2025
Home
News | Pharmaceuticals

Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...

Home September 23, 2025
Home
News | Pharmaceuticals

Sept. 2, 2025 —Corsera Health, Inc. has announced its launch with a mission to extend healthspan through cardiovascular ...

Home September 05, 2025
Home
News | Pharmaceuticals

July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...

Home July 10, 2024
Home
News | Pharmaceuticals

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

Home June 05, 2024
Home
News | Pharmaceuticals

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

Home May 24, 2024
Home
News | Pharmaceuticals

May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...

Home May 06, 2024
Home
News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
Subscribe Now